XBiotech is pioneering a new era in the discovery and development of targeted antibodies based on its breakthrough True Human™ technology. The company's mission is to revolutionize the way antibody medicines are discovered and commercialized by advancing its robust pipeline of truly natural human antibodies for treating serious diseases such as cancer, inflammatory conditions and infectious diseases.
XBiotech's lead product, Xilonix™, is a potential breakthrough antibody therapy that is currently the subject of two pivotal clinical studies for treating patients with advanced colorectal cancer. Xilonix™ specifically targets and neutralizes interleukin-1 alpha (IL-1a), a molecule known to promote angiogenesis, growth and spread of tumors, as well as mediate symptoms such as metabolic dysregulation, fatigue and anxiety associated with advanced cancer.
The Company's broad pipeline of True Human™ antibodies are able to potentially deliver unmatched safety and efficacy because they are cloned directly from individual donors who possess natural immunity against certain targeted diseases. As such, True Human™ antibodies retain their natural physiology and tolerance profile, having passed the rigors of immune selection in the body.
The Hippocratic notion that medicine "should never do harm" is a cornerstone to how we approach drug development. This includes the belief that cutting-edge medicine should work in a targeted way to make patients feel better, not worse. We believe this very old principle should continue to shape the future of medicine.